Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18930361 | 0.94 | HRH3 (0.35) | HRH3KCNH2ALDH1A1SYKOPRM1 | |
| SCHEMBL15721224 | 0.81 | NCF1 (0.38) | TLR7SYKOPRM1 | |
| SCHEMBL20795837 | 0.78 | EPHX1 (0.43) | KCNH2SYKOPRM1 | |
| SCHEMBL13212863 | 0.76 | HRH3 (0.38) | HRH3KCNH2ALDH1A1OPRM1 | |
| SCHEMBL25513773 | 0.75 | PIK3CA (0.38) | HRH3KCNH2OPRM1 | |
| SCHEMBL24671069 | 0.73 | HRH3 (0.37) | HRH3KCNH2ALDH1A1OPRM1 | |
| SCHEMBL14725147 | 0.70 | HRH3 (0.41) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL1261174 | 0.70 | HRH3 (0.44) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL2603283 | 0.70 | POLB (0.38) | HRH3KCNH2 | |
| SCHEMBL20348267 | 0.70 | HRH3 (0.40) | HRH3KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | Libertas Bio, Inc. | 2016-09-08 | — | — | US | disclosed |
| US-9382277-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729079-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ENDO PHARMACEUTICALS INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | ENDO PHARMACEUTICALS INC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257691-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | TLR9 238/4885TLR8 135/4885TLR7 83/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | TLR9 2337/4885TLR8 4074/4885TLR7 1176/4885 |
| US-20140221315-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | TLR9 238/4885TLR8 135/4885TLR7 83/4885 |
| US-20130053346-A1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND METHODS OF USE THEREOF | THPO, TYMP, TYMS | TLR9 238/4885TLR8 135/4885TLR7 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.